A Higher, Faster, Longer Fish Oil
Fish oil has been studied for decades for its many health benefits including preventing and managing heart disease, lowering blood pressure, supporting eye health for the elderly, reducing triglycerides, and slowing the development of plaque in the arteries.*
The delivery of fish oil has had a recent breakthrough with a novel monoglyceride delivery system called MaxSimil® PLATform (Patented Lipid Absorption Enhancement Technology). This technology created by Ingenutra and distributed exclusively by Neptune Wellness mimics the biological digestive process and delivers absorption-ready monoglyceride-rich omega-3 with three-times greater eiocosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) absorption rates than equivalent doses of other ethyl ester (EE) forms of fish oil.
Monoglyceride fish oil provides patients the convenience of swallowing fewer and in some cases smaller capsules. It also means patients’ bodies can access the essential fatty acids in a much more efficient way, including patients with malabsorption conditions or compromised digestive health. Patients suffering from these types of conditions can, for example, include the elderly, celiac or cystic fibrosis patients, those with gallstones or chronic pancreatitis among others.
Due to the fact that monoglyceride fish oils are intrinsically emulsifiers and are, by nature, in a readily absorbable form, they can bypass the body’s normal fat digestion process. These qualities make monoglyceride fish oils an excellent method for delivering omega-3 fatty acids.
In Vitro and In Vivo Animal Studies
The ability of MaxSimil-enhanced EPA and DHA to positively influence growth inhibition and apoptosis in colorectal, breast, lung, and prostate diseased cell lines was first demonstrated in a series of in vitro studies.[2-4] Researchers subsequently set out to demonstrate efficacy in animal models after oral administration. In three separate animal models, MaxSimil EPA and DHA forms showed superior activity on diseased cell-line growth inhibition and cytokine production when compared to control, corn oil, krill oil, or the parent forms EE EPA and EE DHA.[2,5,6,7] These in vivo animal studies proved that orally supplemented MaxSimil EPA and DHA were well-absorbed and bioactive. Researchers postulated that the observed superior effects of MaxSimil EPA and DHA forms were the result of enhanced absorption, and they set out to prove this hypothesis.*
Preclinical Bioavailability Studies
An in-vivo pharmacokinetic studies in rodents involved a comparison between MaxSimil DHA fish oil and its parent EE DHA fish oil and an analysis of blood concentrations of DHA over time. The dose used was equivalent to a human dose of 3 g/day. Researchers found that MaxSimil DHA fish oil had a three-times higher peak concentration (6 percent versus 2 percent) and a three-times higher saturation potential at the high dose (10 percent versus 3 percent), and a three-times higher absorption rate than its parent DHA fish oil. This research demonstrated superior bioavailability and presumably better exposure of cells to DHA.*
Clinical Bioavailability Study
A single-dose, double-blind, randomized, crossover pharmacokinetic clinical study was performed in 20 healthy males and females aged between 19 and 60 years. After a 12-hour fast and PK baseline blood sampling, all subjects were administered 6 softgels per treatment (MaxSimil product or EE comparator, with a seven day washout period) comprising a total of 3650 mg EPA + DHA. Parameters studied were plasma EPA and DHA concentration (as percent of total fatty acids), maximum concentration (Cmax), and area under the curve (AUC). As expected due to its pre-digested nature, a faster increase in EPA and DHA blood concentration was seen with the MaxSimil product compared to the EE. The MaxSimil-treated group achieved three-fold higher baseline-adjusted values for Cmax and AUC than the comparator EE.
Not only did this study confirm the bioavailability findings in the animal study, but it also demonstrated that after 24 hours, the MaxSimil fish oil maintained two-three times higher blood levels of EPA and DHA than the EE fish oil. This means that, given a daily dose, circulating EPA and DHA levels can be expected to ramp up over time and remain high with steadily increasing exposure of cells to EPA, DHA, and their metabolites. Based on the results of the bioavailability studies, an individual would get more EPA and DHA from MaxSimil fish oil than from EE fish oil gram for gram. Furthermore, as shown in the animal studies, one could anticipate enhanced effects.*
In vitro and animal studies have demonstrated the positive effects of MaxSimil fish oil on airway immune response (e.g., IgE, leukocytes); the expression of COX-2, NF-kB, cytokines (e.g., IL-6, IL-8), MUC5AC, and mucin; and Ca(2+) hypersensitivity in lung tissues.[6,9-11] In other research, rats subjected to eight weeks of a high-fat, high-carbohydrate diet were either not supplemented or provided 3 g/day of MaxSimil DHA. Compared to the data from the non-supplemented group, the data from the MaxSimil DHA supplemented group clearly showed a positive impact on cardiovascular health parameters. Measures included blood pressure, heart rate, serum lipid levels, cytokine production, aortic wall thickness, and DHA:AA ratio in aortic tissue. The latter correlates with the production of resolvin D2 and D3 metabolites.*
Researchers recently studied the ability of MaxSimil-DHA to correct fat malabsorption and malnutrition in cystic fibrosis patients . These patients suffer from exocrine pancreatic insufficiency (EPI), a condition that prevents the proper production of enzymes required by the body to break down and absorb nutrients and dietary fatty acids. This insufficiency leads to an increase in inflammation due to an imbalance in the arachidonic acid/DHA ratio. The study was conducted on two groups of 10 patients who received either MaxSimil-DHA or a placebo (sunflower oil) for a period of 60 days. Lipid analyses revealed an increase in the DHA content of the red blood cells and a decrease in inflammatory markers, plasma human leukocyte elastase (pHLE) complexes and interleukin-6 (IL-6) expression levels in blood samples of patients supplemented with MaxSimil-DHA compared to placebo.*
As mentioned, the arachidonic acid (AA) to EPA ratio (AA:EPA) is a measure of cellular inflammation. Limited clinical data consisting of case studies from medical practices in the US suggest that reductions in this ratio are possible in just four weeks of supplementation with one 1300 mg MaxSimil monoglyceride fish oil/softgel twice daily. More data is needed to confirm.*
A Note About Resolvins and Other EPA and DHA Metabolites
Specialized pro-resolving lipid mediators, such as resolvins, protectins, and maresins, are EPA, DHA and DPA metabolites naturally produced in-vivo through enzymatic conversion. These mediators aid the body’s “clean-up” response to the arachidonic acid cascade. Rather than supplying a single molecule or metabolite, which would mirror the pharmaceutical model, MaxSimil-enhanced fish oils provide all the functional benefits of EPA and DHA as well as enable the body to synthesize these beneficial metabolites efficiently by virtue of its ample tissue and circulating supply pools.
XYMOGEN, a family-owned US manufacturer and distributor of a comprehensive line of nutraceutical formulas in the professional channel, was one of the first to offer MaxSimil in an array of formulas called Omega MonoPure®. Each enteric-coated fish-gelatin softgel includes MaxSimil-enhanced fish oil with no additional ingredients, carriers, or excipients. The Omega MonoPure line is also International Fish Oil Standards (IFOS) five-star certified, non-GMO, certified sustainable from Scandinavia, and antibiotic-free.
- Brunet S, Chamoun R, Fortin S, et al. MaxSimil®: A novel, patented natural platform for enhanced absorption of omega-3s. Single-dose, double-blind, 2-way crossover pilot pharmacokinetic study on healthy subjects under normal diet. Sherbrooke (Québec), Canada: Ingenutra; 2018. [Unpublished, on file]
- Morin, C., Rousseau, É. and Fortin, S., 2013. Anti-proliferative effects of a new docosapentaenoic acid monoacylglyceride in colorectal carcinoma cells. Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA), 89(4), pp.203-213.
- Fortin S, inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. US patent 8,119,690. February 21, 2012.
- Fortin S, inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. US patent 8,329,747. December 11, 2012.
- Morin, C., Blier, P.U. and Fortin, S., 2015. Eicosapentaenoic acid and docosapentaenoic acid monoglycerides are more potent than docosahexaenoic acid monoglyceride to resolve inflammation in a rheumatoid arthritis model. Arthritis research & therapy, 17(1), p.142.
- Morin, C., Fortin, S., Cantin, A.M. and Rousseau, É., 2011. Docosahexaenoic acid derivative prevents inflammation and hyperreactivity in lung: implication of PKC-Potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17 kD in asthma. American journal of respiratory cell and molecular biology, 45(2), pp.366-375.
- Morin, C., Rodríguez, E., Blier, P.U. and Fortin, S., 2017. Potential Application of Eicosapentaenoic Acid Monoacylglyceride in the Management of Colorectal Cancer. Marine drugs, 15(9), p.283.
- Fortin S, inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof. US patent 8,198,324. June 12, 2012.
- Morin, C., Fortin, S., Cantin, A.M. and Rousseau, E., 2013. MAG‐EPA resolves lung inflammation in an allergic model of asthma. Clinical & Experimental Allergy, 43(9), pp.1071-1082.
- Morin, C., Cantin, A.M., Rousseau, É., Sirois, M., Sirois, C., Rizcallah, E. and Fortin, S., 2015. Proresolving Action of Docosahexaenoic Acid Monoglyceride in Lung Inflammatory Models Related to Cystic Fibrosis. American journal of respiratory cell and molecular biology, 53(4), pp.574-583.
- Morin, C., Fortin, S. and Rousseau, E., 2012. New omega-3 derivatives reduce airway inflammation and prevent rho-kinase activation in an allergic model of asthma. J Aller Ther, 3(S1), p.003.
- Morin, C., Rousseau, E., Blier, P.U. and Fortin, S., 2015. Effect of docosahexaenoic acid monoacylglyceride on systemic hypertension and cardiovascular dysfunction. American Journal of Physiology-Heart and Circulatory Physiology, 309(1), pp.H93-H102.
- Morin, C., Cantin, A.M., Vézina, F.A. and Fortin, S., 2018. The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients. Marine drugs, 16(6), p.184.
- Weylandt, K.H., Chiu, C.Y., Gomolka, B., Waechter, S.F. and Wiedenmann, B., 2012. Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. Prostaglandins & other lipid mediators, 97(3-4), pp.73-82.